


## Noriko Satake, M.D.

<b>Clinical Interests</b>	Dr. Satake is a board certified pediatric hematologist and oncologist offering care for children with various cancers. She is also interested in developing new treatments and cell therapies.
<b>Research/Academic Interests</b>	Dr. Satake's research focuses on understanding molecular mechanisms in childhood cancers (and cancer stem cells) and identifying novel targets. Her ultimate goal is to develop more effective treatments with fewer side effects than current therapies for children with cancers. She has established a tissue repository and developed a series of patient-derived leukemia xenograft mouse models, which serve as precious tools to conduct her research.
<b>Title</b>	Associate Professor
<b>Specialty</b>	Pediatrics, Pediatric Hematology/Oncology, Hematology/Oncology
<b>Department</b>	<a href="#">Pediatrics</a>
<b>Division</b>	Pediatric Hematology/Oncology
<b>Center/Program Affiliation</b>	<a href="#">Stem Cell Research Program</a> <a href="#">Stem Cell Transplant Program</a> <a href="#">UC Davis Children's Hospital</a> <a href="#">UC Davis Comprehensive Cancer Center</a>
<b>Address/Phone</b>	UC Davis Comprehensive Cancer Center, 2279 45th Street Sacramento, CA 95817 <b>Phone:</b> 916-734-5959
<b>Additional Phone</b>	Clinic Phone: 916-703-2601 Clinic Fax: 916-451-3014 Physician Referrals: 800-4-UCDAVIS (800-482-3284)
<b>Languages</b>	Japanese
<b>Education</b>	M.D., Asahikawa Medical College, Asahikawa, Japan 1990
<b>Residency</b>	Pediatrics, Hokkaido University School of Medicine, Sapporo, Japan 1990-1994 Pediatrics, Wright State University, Dayton OH 2001-2003
<b>Fellowships</b>	Hematology/Oncology, Saitama Cancer Center Hospital, Saitama, Japan 1994-1996 Pediatric Hematology/Oncology, UCLA, Los Angeles CA 2003-2006
<b>Board Certifications</b>	American Board of Pediatrics



## Noriko Satake, M.D.

American Board of Pediatrics, Pediatric Hematology-Oncology

### Honors and Awards

Distinguished Alumni Award (Asahikawa Medical School, Japan), 2016

### Select Recent Publications

Yoshida S, Duong C, Oestergaard M, Fazio M, Chen C, Peralta R, Guo S, Seth PP, Li Y, Beckett L, Nitin N, Satake N. MXD3 Antisense Oligonucleotide With Superparamagnetic Iron Oxide Nanoparticles: A New Targeted Approach for Neuroblastoma. *Nanomedicine*. 2020 Feb;24:102127. doi:10.1016/j.nano.2019.102127. Epub 2019 Nov 26.


Yoshida S, Tuscano E, Duong C, Chung J, Li Y, Beckett L, Tuscano JM, Satake N. Efficacy of an Anti-CD22 Antibody-Monomethyl Auristatin E Conjugate in a Preclinical Xenograft Model of Precursor B cell Acute Lymphoblastic Leukemia. *Leuk Lymphoma*. 2017 May;58(5):1254-1257. doi:10.1080/10428194.2016.1235273. Epub 2016 Oct 5.

Duong C, Yoshida S, Chen C, Barisone G, Diaz E, Li Y, Beckett L, Chung J, Antony R, Nolta J, Nitin N, Satake N. Novel Targeted Therapy for Neuroblastoma: Silencing the MXD3 Gene Using siRNA. *Pediatr Res*. 2017 Sep;82(3):527-535. doi:10.1038/pr.2017.74. Epub 2017 May 31.

Satake N, Duong C, Yoshida S, Oestergaard M, Chen C, Peralta R, Guo S, Seth PP, Li Y, Beckett L, Chung J, Nolta J, Nitin N, Tuscano JM. Novel Targeted Therapy for Precursor B Cell ALL: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate. *Mol Med*. 2016 Oct;22:632-642. doi:10.2119/molmed.2015.00210. Epub 2016 Jul 22.

Barisone GA, Satake N, Lewis C, Duong C, Chen C, Lam K, Nolta J, Diaz E. Loss of MXD3 Induces Apoptosis of Human Precursor B cell Acute Lymphoblastic Leukemia cells. *Blood Cells Mol Dis*. 2015 Apr;54(4):329-335. Published online 2014 Dec 20. doi:10.1016/j.bcmed.2014.12.002.

Satake N, Duong C, Chen C, Barisone GA, Diaz E, Tuscano J, Rocke DM, Nolta J, Nitin N. Targeted Therapy with MXD3 siRNA, antiCD22 Antibody, and Nanoparticles for Precursor B-Cell Acute Lymphoblastic Leukemia. *Br J Haematol*. 2014 Nov;167(4):487-499. doi:10.1111/bjh.13066.



## Noriko Satake, M.D.

Epub 2014 Sep 8.

Satake N, Duong C, Yoshida S, Davis R, Liu S, Van Dyke J, McLaughlin B, Nolta J, Nitin N, Tepper C. Leukemia Stem Cells in Acute Lymphoblastic Leukemia: Unveiling Hierarchical Structure at Single Cell Resolution. *Blood*. 2014 Dec 6;124(21):4786. doi:10.1182/blood.V124.21.4786.4786.

Yoshida S, Tuscano ET, Duong C, Tuscano JM, Satake N. Efficacy of an Anti-CD22 Antibody-Monomethyl Auristatin E Conjugate in a Preclinical Xenograft Model of Precursor B cell Acute Lymphoblastic Leukemia. *Blood*. 2014;124(21):971. doi:10.1182/blood.V124.21.971.971.

Duong C, Oestergaard M, Yoshida S, Chen C, Nolta J, Guo S, Seth P, Nithin N, Tuscano JM, Satake N. Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugates. *Blood*. 2014;124(21):3719. doi:10.1182/blood.V124.21.3719.3719.

Duong C, Chen C, Yoshida S, Barisone G, Nolta J, Dia E, Nitin N, Satake N. Abstract 5423: Novel Targeted Therapy for Neuroblastoma: Silencing the MXD3 Gene Using siRNA. *Cancer Res*. 2014; 74(19 Suppl):Abstract nr 5423. doi:10.1158/1538-7445.AM2014-5423 Published October 2014.

© 2022 UC Regents